Skip to main content
Premium Trial:

Request an Annual Quote

CMS Nominee

President Joe Biden is to nominate Chiquita Brooks-LaSure to lead the Centers for Medicare and Medicaid Services, Politico reports.

According to CNN, Brooks-LaSure is currently a managing director at the professional services firm Manatt Health and also was part of the Biden-Harris transition team that reviewed the Department of Health and Human Services, of which CMS is part. It adds that she previously served at CMS during the Obama Administration and worked on the 2010 Affordable Care Act, and before that was a staffer for the House Ways and Means Committee.

As head of the trillion-dollar agency, Brooks-LaSure would, if confirmed, oversee Medicare and Medicaid and be responsible for much of the ACA, including the insurance marketplace, the Washington Post adds. CNN notes she would also be tasked with undoing many of the changes made by the previous head of CMS, Seema Verma, such as cutting ACA marketing funding and narrowing the open enrollment period.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.